Connection
Allen Cohn to Epithelial-Mesenchymal Transition
This is a "connection" page, showing publications Allen Cohn has written about Epithelial-Mesenchymal Transition.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.438 |
|
|
|
-
Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271.
Score: 0.438